Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

OBJECTIVE: To ascertain the role of inflammation in the response to ocrelizumab in primary-progressive multiple sclerosis (PPMS). METHODS: Multicenter prospective study including 69 patients with PPMS who initiated ocrelizumab treatment, classified according to baseline presence [Gd+, n=16] or absen...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Velasco, José I., Monreal, Enric, Kuhle, Jens, Meca-Lallana, Virginia, Meca-Lallana, José, Izquierdo, Guillermo, Oreja-Guevara, Celia, Gascón-Giménez, Francisco, Sainz de la Maza, Susana, Walo-Delgado, Paulette E., Lapuente-Suanzes, Paloma, Maceski, Aleksandra, Rodríguez-Martín, Eulalia, Roldán, Ernesto, Villarrubia, Noelia, Saiz, Albert, Blanco, Yolanda, Diaz-Pérez, Carolina, Valero-López, Gabriel, Diaz-Diaz, Judit, Aladro, Yolanda, Brieva, Luis, Íñiguez, Cristina, González-Suárez, Inés, Rodríguez de Antonio, Luis A, García-Domínguez, José M., Sabin, Julia, Llufriu, Sara, Masjuan, Jaime, Costa-Frossard, Lucienne, Villar, Luisa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977599/
https://www.ncbi.nlm.nih.gov/pubmed/35386690
http://dx.doi.org/10.3389/fimmu.2022.842354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977599/
https://www.ncbi.nlm.nih.gov/pubmed/35386690
http://dx.doi.org/10.3389/fimmu.2022.842354

Ejemplares similares